PuSH - Publication Server of Helmholtz Zentrum München: OX40L blockade protects against inflammation-driven fibrosis.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Elhai, M.* ; Avouac, J.* ; Hoffmann-Vold, A.M.* ; Ruzehaji, N.* ; Amiar, O.* ; Ruiz, B.* ; Brahiti, H.* ; Ponsoye, M.* ; Fréchet, M.* ; Burgevin, A.* ; Pezet, S.* ; Sadoine, J.* ; Guilbert, T.* ; Nicco, C.* ; Akiba, H.* ; Heissmeyer, V. ; Subramaniam, A.* ; Resnick, R.* ; Molberg, O.* ; Kahan, A.* ; Chiocchia, G.* ; Allanore, Y.*

OX40L blockade protects against inflammation-driven fibrosis.

Proc. Natl. Acad. Sci. U.S.A. 113, E3901-E3910 (2016)

Publ. Version/Full Text

Supplement

DOI

PMC

	Open Access Gold

Abstract
Metrics
Extra information

Treatment for fibrosis represents a critical unmet need, because fibrosis is the leading cause of death in industrialized countries, and there is no effective therapy to counteract the fibrotic process. The development of fibrosis relates to the interplay between vessel injury, immune cell activation, and fibroblast stimulation, which can occur in various tissues. Immunotherapies have provided a breakthrough in the treatment of immune diseases. The glycoprotein OX40-OX40 ligand (OX40L) axis offers the advantage of a targeted approach to costimulatory signals with limited impact on the whole immune response. Using systemic sclerosis (SSc) as a prototypic disease, we report compelling evidence that blockade of OX40L is a promising strategy for the treatment of inflammation-driven fibrosis. OX40L is overexpressed in the fibrotic skin and serum of patients with SSc, particularly in patients with diffuse cutaneous forms. Soluble OX40L was identified as a promising serum biomarker to predict the worsening of lung and skin fibrosis, highlighting the role of this pathway in fibrosis. In vivo, OX40L blockade prevents inflammation-driven skin, lung, and vessel fibrosis and induces the regression of established dermal fibrosis in different complementary mouse models. OX40L exerts potent profibrotic effects by promoting the infiltration of inflammatory cells into lesional tissues and therefore the release of proinflammatory mediators, thereafter leading to fibroblast activation.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

9.423

2.565